LTQ Orbitrap XL ETD mass spectrometer

描述（由申请人提供）：肯塔基州大学（英国）医学院的蛋白质组学核心机构要求以947，163美元购买带有Eksigent nano-HPLC的LTQ Orbitrap XL/ETD混合质谱仪。该应用程序的目标是提供先进的质谱分析能力，以满足英国19个高生产率的NIH资助的研究人员的蛋白质组学需求。LTQ Orbitrap/ETD混合质谱仪结合了新型线性离子阱（LTQ）、新型高精度静电离子阱（Orbitrap）质量分析仪和创新的电子转移解离（ETD）技术。与现有的用于蛋白质和肽分析的质谱仪相比，该混合仪器在单个实验中同时提供高灵敏度（阿托摩尔）、高光谱重复率、高质量分辨率（60，000 HWFM）、高质量准确度（<5 ppm）和互补的碎片技术（CID和ETD）。该仪器达到了一个新的水平的灵敏度和信心，以确定肽和蛋白质。此外，ETD技术提供了多种独特的优势。特别是它可以在片段化过程中保留肽上的翻译后修饰，并允许鉴定精确的修饰位点。该设备将为蛋白质组学核心设施提供最先进的能力，并提高该设施的能力，以满足不断增加的研究支持数量和强度。该设备对于这些正在进行的研究计划以及刺激和实现蛋白质鉴定，翻译后修饰表征，基因发现和功能蛋白质组学的新合作研究计划至关重要。目前，在英国或肯塔基州的任何大学都没有LTQ Orbitrap/ETD质谱仪。该仪器的购买对于英国人类疾病和基础研究的蛋白质组学研究计划的持续扩展和增强至关重要。如本申请所述，来自12个不同部门的19名NIH资助的研究人员对该质谱仪有特定需求。所要求的仪器将对我们机构的研究能力产生重大影响。 为确保最大限度的使用和适当的维护，仪器将放置在PI实验室旁边的Proteomics Core中。PI在生物质谱/蛋白质组学领域拥有超过10年的经验。组建了一个由内部和外部成员组成的咨询委员会，为共同文书的使用提供总体指导。该大学承诺为仪器的长期维护和运行提供财政支持。该仪器支持的研究涵盖广泛的生物学和生物医学研究，包括专注于神经系统疾病，癌症，糖尿病，心血管疾病，病毒学，眼科疾病和妇女健康的尖端计划。将该仪器添加到英国医学中心的蛋白质组学核心设施将显著提高这些研究项目的生产力和进展，从而推进NIH改善公共健康的使命。 该提案的资助将导致雇用和/或保留六个以上的全职职位，其中至少一个在肯塔基州大学，四个在赛默飞世尔科技公司，一个在Eksigent技术公司。因此，该提案符合《复苏法》供资的标准。 仪器制造商（Thermo Fisher Scientific和Eksigent Technologies）承诺对环境负责。特别是，与其他分流色谱仪器相比，Eksigent Technologies生产的无分流纳米HPLC使用的有机溶剂显著减少，从而产生的化学废物减少数百至数千倍。此外，将由所要求的仪器启用和支持的生物医学研究计划将使发现导致美国人更好的健康。综上所述，这项申请的资助将使美国和世界更健康、更清洁、更安全。 公共卫生相关性：肯塔基州大学（英国）医学院的蛋白质组学核心设施申请947，163美元，以购买带有Eksigent nano-HPLC的LTQ Orbitrap XL ETD混合质谱仪。该应用程序的目标是提供先进的质谱分析能力，以满足英国19个高生产率的NIH资助的研究人员的蛋白质组学需求。该仪器支持的研究涵盖广泛的生物学和生物医学研究，包括专注于神经系统疾病，癌症，糖尿病，心血管疾病，病毒学，眼科疾病和妇女健康的尖端计划。将该仪器添加到蛋白质组学核心设施将显著提高这些研究项目的生产力和进展，从而推进NIH改善公共健康的使命。该提案的资金将导致雇用和/或保留六个以上的全职职位，符合《复苏法》的意图。所要求的仪器是环境友好型的。综上所述，这项申请的资助将使美国和世界更健康、更清洁、更安全。

DESCRIPTION (provided by applicant): The Proteomics Core Facility at the University of Kentucky (UK) College of Medicine requests $947,163 to acquire a LTQ Orbitrap XL/ETD hybrid mass spectrometer with an Eksigent nano-HPLC. The goal of this application is to provide advanced mass spectrometry capabilities to meet the proteomics needs of 19 highly productive NIH-funded investigators at UK. The LTQ Orbitrap/ETD hybrid mass spectrometer is a combination of a new linear ion trap (LTQ), a novel and high precision electrostatic ion trap (Orbitrap) mass analyzer, and innovative electron transfer dissociation (ETD) technology. In comparison to the existing mass spectrometers for protein and peptide analysis, this hybrid instrument simultaneously provides high sensitivity (attomoles), high spectrum repetition rates, high mass resolution (60,000 HWFM), high mass accuracy (< 5ppm), and complementary fragmentation techniques (both CID and ETD) during a single experiment. The instrumentation reaches a new level of sensitivity and confidence for identifying peptides and proteins. Moreover, the ETD technology provides multiple unique advantages. Particularly it can preserve the post-translation modifications on peptides during fragmentation and allow the identification of exact modification sites. This equipment will provide state-of-the-art capabilities to the Proteomics Core Facility and enhance the ability of the facility to meet an ever-increasing volume and intensity of research support. This equipment is essential to these ongoing research programs and to stimulating and enabling new collaborative research initiatives on protein identification, posttranslational modification characterization, gene discovery, and functional proteomics. Currently, there is no LTQ Orbitrap/ETD mass spectrometer at UK or any universities in the Commonwealth of Kentucky. The purchase of the instrument is critical to the continuing expansion and enhancement of the proteomics research program in human disease and basic research at UK. As described in this application, 19 NIH-funded investigators from 12 different departments have specific needs for this mass spectrometer. The requested instrument will have a major impact on research capabilities at our institution. To ensure the maximal usage and proper maintenance, the instrument will be housed in the Proteomics Core next to the laboratory of the PI. The PI has over 10 years experience in the area of biological mass spectrometry/proteomics. An Advisory Committee with both internal and external members is assembled for overall guidance for the usage of the shared instrument. Financial support for the long term maintenance and operation of the instrument is committed from the University. The research to be supported by this instrument spans a wide spectrum of biological and biomedical research, including cutting-edge programs focused on neurological disorders, cancer, diabetes, cardiovascular disease, virology, eye diseases, and women's health. The addition of this instrument to the Proteomics Core Facility at UK Medical Center will significantly enhance the productivity and progress of these research programs, thus advancing the NIH mission to improve public health. The funding of this proposal will lead to the hiring and/or retention of more than six full-time positions, including at least one in the University of Kentucky, four at Thermo Fisher Scientific, and one with Eksigent Technologies. Thus this proposal fits the criteria for Recovery Act funding. The manufacturers of the instrumentation (Thermo Fisher Scientific and Eksigent Technologies) are committed to being environmentally responsible. In particular, the splitless nano-HPLC manufactured by Eksigent Technologies uses significantly less organic solvents compared to other split-flow chromatography instruments, thus generating hundreds- to thousands-fold less chemical waste. Moreover, the biomedical research programs that will be enabled and supported by the requested instrumentation will make discoveries leading to better health of Americans. In summary, the funding of this application will make the United States and the world healthier, cleaner and safer. PUBLIC HEALTH RELEVANCE: The Proteomics Core Facility at the University of Kentucky (UK) College of Medicine requests $947,163 to acquire a LTQ Orbitrap XL ETD hybrid mass spectrometer with an Eksigent nano-HPLC. The goal of this application is to provide advanced mass spectrometry capabilities to meet the proteomics needs of 19 highly productive NIH-funded investigators at UK. The research to be supported by this instrument spans a wide spectrum of biological and biomedical research, including cutting-edge programs focused on neurological disorders, cancer, diabetes, cardiovascular disease, virology, eye diseases, and women's health. The addition of this instrument to the Proteomics Core Facility will significantly enhance the productivity and progress of these research programs, thus advancing the NIH mission to improve public health. The funding of this proposal will lead to the hiring and/or retention of more than six full-time positions, meeting the intention of the Recovery Act. The requested instruments are environmentally friendly. In summary, the funding of this application will make the United States and the world healthier, cleaner and safer.